Titomic (ASX:TTT) signs US military CRADA and the defence pivot gets real

Huntsville facility now anchors a joint research framework tied directly to the 2026 National Defense Strategy budget

Titomic (ASX:TTT) has just signed a multi-year Cooperative Research and Development Agreement, or CRADA, with a US military research organization out of its Huntsville, Alabama facility. The framework covers joint research into cold spray manufacturing, advanced materials, in-field repairs and what the Department of War calls expeditionary manufacturing.

For a small-cap additive manufacturing company that has spent years telling investors its Titomic Kinetic Fusion technology has defence applications, this is the kind of paperwork that starts to validate the pitch. A CRADA is not a purchase order, and we will come back to that distinction. But it is the formal mechanism the US government uses to put its own researchers, facilities and intellectual property alongside a private partner, and that is a meaningful step up from a pilot.

The agreement is explicitly tied to the 2026 National Defense Strategy and its budget priorities around missiles, munitions and sustainment. That alignment matters because it tells investors which budget line Titomic is now trying to plug into.

The company also chose its anchor well. Huntsville sits inside one of the densest defence, missile and aerospace clusters in the US, which is exactly where a cold spray repair and manufacturing business needs to be.

What a CRADA actually buys Titomic, and what it doesn’t

A CRADA gives Titomic structured access to US military researchers, test facilities and data, in exchange for the company contributing its own technology and people. The key point is that it is a collaboration framework, not a revenue contract. No dollar value is attached in the announcement.

What it does buy is credibility and proximity. Cold spray, which is the process of firing metal powder at supersonic speeds onto a surface to build up or repair components without melting them, is a technology the US military has been quietly evaluating for years. Getting inside the tent through a formal agreement makes Titomic a much more natural candidate when actual sustainment and manufacturing contracts get awarded.

Our take is that investors should treat this as a pipeline catalyst rather than an earnings catalyst. The revenue, if it comes, sits on the other side of successful joint demonstrations.

Why missiles and sustainment are the right budget lines to chase

The 2026 National Defense Strategy puts heavy weight on rebuilding the US industrial base for munitions and on extending the life of existing platforms through better sustainment. Both of those are problems cold spray is genuinely well suited to solve.

Repairing worn or damaged metal parts in the field, rather than shipping them back to a depot, is one of the clearest commercial use cases for Titomic Kinetic Fusion. So is rapidly building up wear surfaces on components used in missile production. The CRADA names exactly these applications, which suggests the scope of work was shaped by what the customer actually needs rather than what Titomic wanted to sell.

The skeptical read is that defence procurement cycles are long, and a CRADA can easily sit in research mode for two or three years before producing a contract. Investors who expect a step-change in FY27 revenue from this single announcement will likely be disappointed.

The Huntsville bet is starting to look smarter

Titomic moved its global headquarters to Huntsville to be near the customer. That decision looked expensive at the time given the company’s modest revenue base and ongoing cash burn.

This CRADA is the first piece of evidence that the geography is paying off. Being physically close to Redstone Arsenal, the missile commands and the prime contractors clustered around Huntsville is precisely the kind of access that opens doors a Melbourne-based pitch deck cannot.

The Investors Takeaway for Titomic

What investors should watch from here is whether the CRADA produces a named program of work with a budget attached, ideally within the next 12 to 18 months. A framework agreement that sits idle is worth very little. A framework that generates two or three funded demonstration projects starts to reshape how the market values this name.

We would also want to see Titomic disclose, where security allows, which specific platforms or components the joint research will target. That kind of specificity is what separates a credible defence supplier from a company still pitching potential. For readers tracking the broader ASX defence and advanced manufacturing theme, we cover more of these names at stocksdownunder.